Which has better valuation & earnings, MEDP or CAI?

Medpace has higher revenue and earnings than Caris Life Sciences. Medpace is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.85 $451.12M $17.06 36.39 Caris Life Sciences $348.89M 21.28 -$68.09M $0.36 72.97

Does the media prefer MEDP or CAI?

In the previous week, Medpace had 24 more articles in the media than Caris Life Sciences. MarketBeat recorded 26 mentions for Medpace and 2 mentions for Caris Life Sciences. Medpace's average media sentiment score of 1.08 beat Caris Life Sciences' score of 0.73 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 21 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CAI or RVTY?

Revvity has higher revenue and earnings than Caris Life Sciences. Revvity is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caris Life Sciences $348.89M 21.28 -$68.09M $0.36 72.97 Revvity $2.86B 4.88 $241.20M $2.10 59.47

Does the media favor CAI or RVTY?

In the previous week, Revvity had 8 more articles in the media than Caris Life Sciences. MarketBeat recorded 10 mentions for Revvity and 2 mentions for Caris Life Sciences. Revvity's average media sentiment score of 1.28 beat Caris Life Sciences' score of 0.73 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, CAI or ICLR?

Icon has higher revenue and earnings than Caris Life Sciences. Icon is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caris Life Sciences $348.89M 21.28 -$68.09M $0.36 72.97 Icon $8.25B 1.60 $229.34M $4.26 40.43

Does the media favor CAI or ICLR?

In the previous week, Icon had 3 more articles in the media than Caris Life Sciences. MarketBeat recorded 5 mentions for Icon and 2 mentions for Caris Life Sciences. Icon's average media sentiment score of 1.57 beat Caris Life Sciences' score of 0.73 indicating that Icon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Icon 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer CAI or TECH?

In the previous week, Bio-Techne had 13 more articles in the media than Caris Life Sciences. MarketBeat recorded 15 mentions for Bio-Techne and 2 mentions for Caris Life Sciences. Bio-Techne's average media sentiment score of 1.31 beat Caris Life Sciences' score of 0.73 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Caris Life Sciences (CAI) Competitors

$26.27 +1.69 (+6.88%)

As of 08/21/2026 04:00 PM Eastern

Compare

CAI vs. MEDP, CRL, RVTY, ICLR, and TECH

Should you buy Caris Life Sciences stock or one of its competitors? Caris Life Sciences's main competitors and comparable companies include Medpace (MEDP), Charles River Laboratories International (CRL), Revvity (RVTY), Icon (ICLR), and Bio-Techne (TECH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Caris Life Sciences compare to Medpace?

Medpace (NASDAQ:MEDP) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Medpace has higher revenue and earnings than Caris Life Sciences. Medpace is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.85	$451.12M	$17.06	36.39
Caris Life Sciences	$348.89M	21.28	-$68.09M	$0.36	72.97

Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

78.0% of Medpace shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 50.0% of Caris Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Medpace had 24 more articles in the media than Caris Life Sciences. MarketBeat recorded 26 mentions for Medpace and 2 mentions for Caris Life Sciences. Medpace's average media sentiment score of 1.08 beat Caris Life Sciences' score of 0.73 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	21 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace presently has a consensus target price of $584.18, suggesting a potential downside of 5.89%. Caris Life Sciences has a consensus target price of $26.33, suggesting a potential upside of 0.24%. Given Caris Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Caris Life Sciences is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Medpace has a net margin of 17.67% compared to Caris Life Sciences' net margin of 10.62%. Medpace's return on equity of 110.15% beat Caris Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Caris Life Sciences	10.62%	18.77%	9.34%

Summary

Medpace beats Caris Life Sciences on 10 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Charles River Laboratories International has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Charles River Laboratories International currently has a consensus price target of $255.65, suggesting a potential downside of 13.41%. Caris Life Sciences has a consensus price target of $26.33, suggesting a potential upside of 0.24%. Given Caris Life Sciences' higher probable upside, analysts clearly believe Caris Life Sciences is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 50.0% of Caris Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Caris Life Sciences has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.51	-$144.34M	-$4.85	N/A
Caris Life Sciences	$348.89M	21.28	-$68.09M	$0.36	72.97

In the previous week, Charles River Laboratories International had 8 more articles in the media than Caris Life Sciences. MarketBeat recorded 10 mentions for Charles River Laboratories International and 2 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.73 beat Charles River Laboratories International's score of 0.45 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caris Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has a net margin of 10.62% compared to Charles River Laboratories International's net margin of -5.96%. Caris Life Sciences' return on equity of 18.77% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Caris Life Sciences	10.62%	18.77%	9.34%

Summary

Caris Life Sciences beats Charles River Laboratories International on 10 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Revvity?

Caris Life Sciences (NASDAQ:CAI) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Revvity had 8 more articles in the media than Caris Life Sciences. MarketBeat recorded 10 mentions for Revvity and 2 mentions for Caris Life Sciences. Revvity's average media sentiment score of 1.28 beat Caris Life Sciences' score of 0.73 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has a net margin of 10.62% compared to Revvity's net margin of 8.16%. Caris Life Sciences' return on equity of 18.77% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Revvity	8.16%	8.34%	5.01%

Caris Life Sciences has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Revvity has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Caris Life Sciences currently has a consensus price target of $26.33, indicating a potential upside of 0.24%. Revvity has a consensus price target of $108.36, indicating a potential downside of 13.23%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Caris Life Sciences is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

86.7% of Revvity shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by company insiders. Comparatively, 0.9% of Revvity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Caris Life Sciences pays an annual dividend of $1.20 per share and has a dividend yield of 4.6%. Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Caris Life Sciences pays out 333.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Revvity pays out 13.3% of its earnings in the form of a dividend.

Revvity has higher revenue and earnings than Caris Life Sciences. Revvity is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$348.89M	21.28	-$68.09M	$0.36	72.97
Revvity	$2.86B	4.88	$241.20M	$2.10	59.47

Summary

Caris Life Sciences beats Revvity on 10 of the 18 factors compared between the two stocks.

How does Caris Life Sciences compare to Icon?

Caris Life Sciences (NASDAQ:CAI) and Icon (NASDAQ:ICLR) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Icon had 3 more articles in the media than Caris Life Sciences. MarketBeat recorded 5 mentions for Icon and 2 mentions for Caris Life Sciences. Icon's average media sentiment score of 1.57 beat Caris Life Sciences' score of 0.73 indicating that Icon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Icon	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Icon has higher revenue and earnings than Caris Life Sciences. Icon is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$348.89M	21.28	-$68.09M	$0.36	72.97
Icon	$8.25B	1.60	$229.34M	$4.26	40.43

Caris Life Sciences has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Icon has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

95.6% of Icon shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by insiders. Comparatively, 44.0% of Icon shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Caris Life Sciences presently has a consensus price target of $26.33, suggesting a potential upside of 0.24%. Icon has a consensus price target of $170.40, suggesting a potential downside of 1.06%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Caris Life Sciences is more favorable than Icon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41

Caris Life Sciences has a net margin of 10.62% compared to Icon's net margin of 3.99%. Caris Life Sciences' return on equity of 18.77% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Icon	3.99%	8.02%	4.56%

Summary

Caris Life Sciences and Icon tied by winning 8 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Bio-Techne?

Caris Life Sciences (NASDAQ:CAI) and Bio-Techne (NASDAQ:TECH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

In the previous week, Bio-Techne had 13 more articles in the media than Caris Life Sciences. MarketBeat recorded 15 mentions for Bio-Techne and 2 mentions for Caris Life Sciences. Bio-Techne's average media sentiment score of 1.31 beat Caris Life Sciences' score of 0.73 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	11 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne has higher revenue and earnings than Caris Life Sciences. Bio-Techne is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$348.89M	21.28	-$68.09M	$0.36	72.97
Bio-Techne	$1.22B	9.32	$181.86M	$1.15	62.89

Caris Life Sciences currently has a consensus target price of $26.33, indicating a potential upside of 0.24%. Bio-Techne has a consensus target price of $68.92, indicating a potential downside of 4.70%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06

Caris Life Sciences has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Caris Life Sciences pays an annual dividend of $1.20 per share and has a dividend yield of 4.6%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Caris Life Sciences pays out 333.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bio-Techne pays out 27.8% of its earnings in the form of a dividend.

Bio-Techne has a net margin of 14.97% compared to Caris Life Sciences' net margin of 10.62%. Caris Life Sciences' return on equity of 18.77% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Bio-Techne	14.97%	13.23%	10.61%

98.9% of Bio-Techne shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Bio-Techne beats Caris Life Sciences on 10 of the 18 factors compared between the two stocks.

Get Caris Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAI vs. The Competition

Export

Metric	Caris Life Sciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.42B	$10.24B	$7.37B	$12.85B
Dividend Yield	N/A	1.46%	2.54%	11.08%
P/E Ratio	72.97	61.54	272.88	24.24
Price / Sales	21.28	110.30	618.96	99.76
Price / Cash	16.48	27.04	78.62	53.99
Price / Book	12.57	37.34	13.05	6.20
Net Income	-$68.09M	$56.67B	$3.47B	$348.59M
7 Day Performance	20.50%	5.24%	2.09%	0.08%
1 Month Performance	67.86%	9.02%	6.64%	3.88%
1 Year Performance	N/A	24.45%	25.02%	16.98%

Caris Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAI Caris Life Sciences	1.825 of 5 stars	$26.27 +6.9%	$26.33 +0.2%	N/A	$7.42B	$348.89M	72.97	1,846	Analyst Upgrade
MEDP Medpace	3.5479 of 5 stars	$578.50 -0.6%	$584.18 +1.0%	+33.9%	$16.15B	$2.53B	33.91	6,200	News Coverage Positive News Insider Trade
CRL Charles River Laboratories International	1.8661 of 5 stars	$279.70 -0.6%	$255.65 -8.6%	+82.7%	$13.37B	$4.02B	N/A	19,700	Trending News Insider Trade
RVTY Revvity	3.4024 of 5 stars	$116.71 -0.7%	$108.36 -7.2%	+32.8%	$13.04B	$2.91B	55.58	11,000	Positive News
ICLR Icon	3.7013 of 5 stars	$163.15 -2.6%	$170.40 +4.4%	-2.0%	$12.49B	$8.25B	38.30	40,100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAI) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caris Life Sciences (CAI) Competitors

CAI vs. MEDP, CRL, RVTY, ICLR, and TECH

How does Caris Life Sciences compare to Medpace?

Summary

How does Caris Life Sciences compare to Charles River Laboratories International?

Summary

How does Caris Life Sciences compare to Revvity?

Summary

How does Caris Life Sciences compare to Icon?

Summary

How does Caris Life Sciences compare to Bio-Techne?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caris Life Sciences (CAI) Competitors

CAI vs. MEDP, CRL, RVTY, ICLR, and TECH

How does Caris Life Sciences compare to Medpace?

Which has better valuation & earnings, MEDP or CAI?

Which has more volatility & risk, MEDP or CAI?

Do insiders and institutionals hold more shares of MEDP or CAI?

Does the media prefer MEDP or CAI?

Do analysts recommend MEDP or CAI?

Is MEDP or CAI more profitable?

Summary

How does Caris Life Sciences compare to Charles River Laboratories International?

Which has more volatility & risk, CRL or CAI?

Do analysts rate CRL or CAI?

Do institutionals & insiders hold more shares of CRL or CAI?

Which has better earnings & valuation, CRL or CAI?

Does the media prefer CRL or CAI?

Is CRL or CAI more profitable?

Summary

How does Caris Life Sciences compare to Revvity?

Does the media favor CAI or RVTY?

Is CAI or RVTY more profitable?

Which has more volatility and risk, CAI or RVTY?

Do analysts prefer CAI or RVTY?

Do institutionals and insiders believe in CAI or RVTY?

Is CAI or RVTY a better dividend stock?

Which has higher valuation and earnings, CAI or RVTY?

Summary

How does Caris Life Sciences compare to Icon?

Does the media favor CAI or ICLR?

Which has stronger earnings & valuation, CAI or ICLR?

Which has more risk & volatility, CAI or ICLR?

Do institutionals and insiders have more ownership in CAI or ICLR?

Do analysts prefer CAI or ICLR?

Is CAI or ICLR more profitable?

Summary

How does Caris Life Sciences compare to Bio-Techne?

Does the media prefer CAI or TECH?

Which has preferable earnings & valuation, CAI or TECH?

Do analysts recommend CAI or TECH?

Which has more risk & volatility, CAI or TECH?

Is CAI or TECH a better dividend stock?

Is CAI or TECH more profitable?

Do institutionals and insiders hold more shares of CAI or TECH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools